Clinical effects of intravenous to oral amiodarone transition strategies in critically ill adult patients.
Serena ArnoukCaitlin AberleDiana AltshulerCristian MerchanGreta L PiperJohn PapadopoulosPublished in: Journal of clinical pharmacy and therapeutics (2019)
Providing IV and PO overlap of amiodarone for a median of 4 hours did not decrease the rate of early tachyarrhythmia recurrence. Future studies are warranted to evaluate the impact of alternative amiodarone dosing strategies on breakthrough tachyarrhythmia.